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Abstract To report on (1) psychometric properties of the
Rosenberg Self-Esteem Scale (SES) studied in adolescents
with ADHD, (2) correlations of SES with ADHD scale
scores, and (3) change in patient-reported self-esteem with
atomoxetine treatment. ADHD patients (12–17 years),
treated in an open-label study for 24 weeks. Secondary
analyses on ADHD symptoms (assessed with ADHD-RS,
CGI, GIPD scales) and self-esteem (SES) were performed.
One hundred and ﬁfty-nine patients were treated. A
dichotomous structure of the SES could be conﬁrmed.
Reliability and internal consistency were moderate to
excellent. Highest coefﬁcients were found for the correla-
tion between SES and GIPD scores. Self-esteem signiﬁ-
cantly increased over time, accompanied by an
improvement of ADHD symptoms and related perceived
difﬁculties. The Rosenberg SES was shown to be internally
consistent, reliable, and sensitive to treatment-related
changes of self-esteem. According to these ﬁndings, self-
esteem may be an important individual patient outcome
beyond the core symptoms of ADHD.
Keywords ADHD  Atomoxetine  Self-esteem 
Self-conﬁdence  Self-liking
Introduction
Attention-deﬁcit/hyperactivity disorder (ADHD) is a dis-
order characterized by inattention, impulsivity, and
hyperactivity that affects 3–7% of school-age children
(American Psychiatric Association 2000). ADHD is asso-
ciated with signiﬁcant impairment of cognitive and psy-
chosocial functioning (Barkley 2002; Biederman and
Faraone 2005) and quality of life (QoL) in patients and
families (Klassen et al. 2004; Matza et al. 2004; Riley et al.
2004; Sawyer et al. 2002). Additionally, there are related
ﬁndings on poor self-esteem in patients with ADHD
(Sawyer et al. 2002; Edbom et al. 2006; Alston and
Romney 1992; Escobar et al. 2005), although research
addressing this relationship has yielded conﬂicting results
(Hoza et al. 1993). Self-esteem has been proposed to be
internalized during the same developmental period in
which ADHD is commonly diagnosed and treated (Bussing
et al. 2000). To date, only a few studies have addressed the
relationship between ADHD and self-esteem as assessed by
an objective patient-reported measure (Alston and Romney
1992; Bussing et al. 2000; Hechtman et al. 1980; Serretti
et al. 2005). In addition, one problem with previous self-
esteem research has been that medication status has not
been reported.
Generally, self-esteem has been deﬁned as a person’s
positive or negative attitude toward oneself (Rosenberg
1965) and has been considered a central construct in
psychological theory, with disagreement about concepts
and dimensions (Tafarodi and Swann 2001). A basic
dichotomy has been proposed by various authors, with,
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dimensions of global self-esteem that are not independent,
however. While the former is based on skills, abilities, and
talents, the latter relates to moral character, attractiveness,
and other aspects of social worth (Tafarodi and Swann
1995, 2001). Genetic versus environmental determinants of
self-esteem have also been investigated in order to com-
plement research that focused on psychosocial factors
(Raevuori et al. 2007; Roy et al. 1995).
Various components and factors were derived from
scales/instruments that have been used to measure self-
esteem. These factors may also vary for different popula-
tions or patient groups: for example, ‘self-conﬁdence’ and
‘self-deprecation’ were described in patients with affective
disorders (Serretti et al. 2005). ‘Self-concept, self-percep-
tion, self-image, and (global) self-worth’ appear as related
terms, concepts, or dimensions in the literature (O’Dea
2006) for adolescent females. ‘Academic and social self-
esteem’ were studied in boys with ADHD (Alston and
Romney 1992). A recent study found statistically signiﬁ-
cant gender differences, with girls reporting lower self-
esteem by means of the ‘I think I am’ scale (Ek et al. 2008).
A number of scales have been developed in order to
measure self-esteem and its dimensions in various patient
groups and clinical conditions, such as the ‘Coopersmith
Self-Esteem Inventory’ (Alston and Romney 1992;
Coopersmith 1967; Grifﬁths et al. 1999; Stern et al. 2007),
‘Self-Liking/Self-Competence Scale’ (Tafarodi and Swann
1995, 2001), and the ‘Rosenberg Self-Esteem Scale’ (SES;
Grifﬁthsetal.1999;Rosenberg 1965;Roy etal.1995; Tapia
et al. 2007). Furthermore, there are some generic scales that
assess self-esteem in subdomains, such as in the ‘Child
Health and Illness Proﬁle-Child Edition’ (CHIP-CE; Riley
et al. 2001, 2006), KINDL (Ravens-Sieberer 2003), and
‘Child Health Questionnaire’ (CHQ; Landgraf 1996).
Among these instruments for assessing self-esteem, the
self-report version ofthe SES (Rosenberg 1965) remains the
most widely used measure. The SES has become popular
duetoitslonghistoryinuse,itsuncomplicatedlanguageand
brevity. The relative simplicity and accessibility of the SES
has favored a considerable number of translations (Schmitt
andAllik2005),aswellasitsapplicationinstudyingvarious
mental disorders (Byrne 1996; Grifﬁths et al. 1999; Serretti
et al. 2005). Reliability and validity of the SES have been
demonstrated in several multilingual samples, including
German subjects (Ferring and Filipp 1996; von Collani and
Herzberg 2003). However, the SES has not been formally
validated for its use in ADHD patients.
The present study was designed to primarily investigate
the degree of ADHD-related difﬁculties, as measured by
the global impression of perceived difﬁculties (GIPD)
instrument, in adolescents with ADHD who were treated
with atomoxetine. Basic results have been published
elsewhere (Dittmann et al. 2006; Dittmann et al. 2009;
Wehmeier et al. 2008). Patient-reported self-esteem was
recorded as a secondary outcome variable that could serve
as an additional parameter studied in comparison and
complementary to the respective standard ADHD core
symptom assessments. The patient-rated assessment of
self-esteem may reﬂect so-called ‘individual patient out-
comes (IPOs)’ for which there has been growing interest
from ADHD experts, regulatory agencies, health insurance
companies, as well as patients and parents.
The objectives of this secondary analysis were (1) to
evaluate the psychometric properties of the SES (Rosenberg
1965), (2) to evaluate correlations with ADHD scales, and
(3) to investigate self-esteem in adolescent patients with
ADHD during atomoxetine treatment.
This self-report approach was also chosen in contrast to
earlier-published parent reports on self-esteem in young
ADHD patients. For availability and feasibility reasons, a
modiﬁed German language version of the SES (10 items;
Ferring and Filipp 1996; von Collani and Herzberg 2003)
has been used in this study focusing on the ‘self-compe-
tence’ and ‘self-liking’ facets of global self-esteem in an
adolescent population of ADHD patients.
Methods
Study design and procedures
This multicenter, open-label, single-arm study was
designed to investigate the degree of ADHD-related difﬁ-
culties, as perceived by patients, parents and physicians, in
adolescents with ADHD who were treated with atomoxe-
tine. Here we focus on the results relating to the self-
esteem of adolescent patients during ADHD treatment, as
assessed by self-report on the SES.
Patients were recruited at 35 investigational sites
throughout Germany (ofﬁce-based, board-certiﬁed child
and adolescent psychiatrists, pediatricians, outpatient
clinics). Boys and girls aged 12–17 years with ADHD as
deﬁned in DSM-IV-TR (American Psychiatric Association
2000), and with a minimum IQ C70 (investigator-esti-
mated) were eligible for the study. The diagnosis was
conﬁrmed using the ‘‘Diagnose-Checkliste Hyperkineti-
sche Sto ¨rungen’’ (Diagnostic Checklist for Hyperkinetic
Disorders), a structured standard instrument based on the
respective DSM-IV-TR and ICD-10 criteria (Do ¨pfner and
Fro ¨lich 2000; DGKJP 2003), which is routinely used for
the diagnostic assessment of ADHD in Germany. Comor-
bid psychiatric and somatic disorders were assessed as part
of a careful clinical examination performed by the inves-
tigator. The exclusion criteria comprised abnormal labo-
ratory ﬁndings, acute or unstable medical conditions,
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123cardiovascular disorder, history of seizures, pervasive
developmental disorder, psychosis, bipolar disorder, sui-
cidal ideation, any medical condition that might increase
sympathetic nervous system activity, or the need for psy-
chotropic medication other than study drug. Patients
already being treated with atomoxetine were also excluded.
The protocol was approved by the ethics committee of the
University of Cologne, Germany, and the study was con-
ducted in accordance with the principles of the Declaration
of Helsinki.
Treatment and assessment procedures
The trial comprised three study periods: following a wash-
out period (I), baseline assessments were carried out with
all the instruments used. During the ﬁrst week, the patients
were treated with atomoxetine at a dose of approximately
0.5 mg/kg per day. During the following 7 weeks, the
recommended atomoxetine dose was 1.2 mg/kg per day,
which could be adjusted within a range of 0.5–1.4 mg/kg
per day, depending on effectiveness and tolerability.
Medication was given once-a-day in the morning. Assess-
ments were carried out weekly during the ﬁrst 2 weeks of
treatment and every 2 weeks, thereafter.
After this 8-week treatment period (II), the physicians
decided in accordance with the patients and their parents
whether the patient was going to continue treatment for
further 16 weeks. Patients who participated in this exten-
sion period (III) continued on the same atomoxetine dose
that again could be adjusted within a range of 0.5–1.4 mg/kg
per day if necessary. During the extension period, three
assessments were carried out at 12, 16, and 24 weeks after
baseline.
Measures
The Rosenberg Self-Esteem Scale (SES) is a widely used
self-esteem scale in social science research (Rosenberg
1965) consisting of ten items, dealing with a person’s
general beliefs about him or herself (Table 1). A validated
German language version was used (Ferring and Filipp
1996), in which the translation of one item had been
revised (von Collani and Herzberg 2003) to improve
consistency with the original version. Each item was rated
on a four-point scale from 0 (do not agree at all) to 3
(completely agree), with high score values reﬂecting strong
self-esteem. Five items were reversely scored from 0
(completely agree) to 3 (do not agree at all). According to a
factor analysis by Serretti et al. (2005), the SES can be
subdivided into two components: a ‘self-conﬁdence’ sub-
scale, including all positively worded items (1, 3, 4, 7, and
10), and a ‘self-liking’ subscale, consisting of all
negatively worded items (2, 5, 6, 8, and 9). For calculation
of the total score, items 2, 5, 6, 8, and 9 needed to be
reversed.
Additionally, ADHD core symptomatology was mea-
sured by various validated scales [Attention-Deﬁcit/
Hyperactivity Disorder Rating Scale-IV-Parent Version:
Investigator-Administered and Scored (ADHD-RS-
IV-Parent:Inv; DuPaul et al. 1998; Faries et al. 2001;
Do ¨pfner et al. 2006), Clinical Global Impression-Severity/
Improvement-Attention-Deﬁcit/Hyperactivity Disorder
Scale (CGI-S/I-ADHD) (Guy 1976; NIMH 1985)]. Fur-
thermore, the degree of ADHD-related difﬁculties was
measured by the Global Impression of Perceived Difﬁcul-
ties (GIPD) instrument, which allows to assess ADHD-
related difﬁculties from a patient, parent, and physician
perspective. The instrument has been validated in pediatric
ADHD patients (Wehmeier et al. 2007, 2008).
Tolerability assessment included monitoring of labora-
tory values and vital signs plus recording of spontaneously
reported adverse events.
Sample size and statistical analyses
The sample size was calculated with respect to the primary
objective of the study preliminarily reported elsewhere
(Dittmann et al. 2006; Dittmann et al. 2009). We assumed
that the true value ofKappa (Fleiss 1981) forthe GIPD scale
is 0.8 (between patients and parents as well as between
patients and physicians). The respective two-sided 95%
conﬁdence intervals were intended to extend 0.1 from the
observed value of Kappa for the estimate to be sufﬁciently
precise. Furthermore, we assumed a true response rate of
50%. Thus, a sample size of 139 patients was considered
Table 1 The Rosenberg Self-Esteem Scale (SES) and its ten items
SES item
no.
SES items
1 On the whole, I am satisﬁed with myself
2 At times, I think I am no good at all
3 I feel that I have a number of good qualities
4 I am able to do things as well as most other people
5 I feel I do not have much to be proud of
6 I certainly feel useless at times
7 I feel that I am a person of worth, at least on an equal
plane with others
8 I wish I could have more respect for myself
9 All in all, I am inclined to feel that I am a failure
10 I take a positive attitude toward myself
Rating: Each item is rated from 0 (do not agree at all) to 3 (completely
agree). The items 1, 3, 4, 7, and 10 comprise the self-conﬁdence
subscale. The items 2, 5, 6, 8, and 9 (self-liking subscale) have to be
reversed prior to calculating the sum score
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123sufﬁcientforthedesiredprecision.Assumingaproportionof
5% of patients with unspeciﬁed data on the GIPD scale, a
sample size of 147 patients was planned.
The data of all patients were evaluated (Full Analysis
Set, FAS), using SAS version 8 or higher. The dataset for
all analyses of changes from baseline to endpoint consisted
of all patients with a baseline measurement and at least one
post-baseline measurement during the 8-week treatment
period.
Evaluation was largely descriptive. All tests of statistical
signiﬁcance were carried out at a nominal level of 5%
using two-tailed test procedures. Two-sided conﬁdence
intervals (CIs) were computed using a 95% conﬁdence
level. All inferences regarding statistical signiﬁcance were
based on comparisons of the 95% CIs. This is equivalent to
signiﬁcance tests with p values and a two-sided a-level of
5%. To avoid correlations of imputed values, only
observed cases analyses were performed. No imputation of
missing values like last observation carried forward
(LOCF) was applied.
Principal component analyses (PCA) and factor anal-
ysis using varimax rotation were performed in order to
conﬁrm the two subscales ‘self-conﬁdence’ (items 1, 3,
4, 7, and 10) and ‘self-liking’ (2, 5, 6, 8, and 9). The
scores for items 2, 5, 6, 8, and 9 were reversed for these
analyses. The correlation structure of the items was
evaluated for untreated patients using the baseline values
and also for treated patients using the values observed at
week 8.
The number and percentage of missing values of the
SES items were computed by pooling all visits for the total
scale SES, i.e., number of observations with at least one
missing item divided by the number of ratings of the SES.
Ceiling and ﬂoor effects for the SES score were calculated
by the percentage of observations with the lowest (=0) and
highest achievable scores (total score = 30, sub-
score = 15) for baseline and week 8 in order to evaluate
patients in an untreated and a treated status. Internal con-
sistency of the SES total score and the subscales was
analyzed by using Cronbach’s alpha (with 95% CI) for
weeks 0 and 8. Test–retest reliability of the SES total score
and the subscales was investigated by comparing weeks 6
and 8 in terms of Pearson’s correlation coefﬁcient and
Cohen’s Kappa (weighted version; both with 95% CI).
Pearson’s correlation coefﬁcient, which is based on the
original values, was used for the total scores in order to
assess the linear association of the more continuous total
scores. Weeks 6 and 8 were chosen because treatment (e.g.,
the dosing of atomoxetine) and disease severity were
expected to be fairly stable during this period. Longer
durations would be more prone to differences in the disease
state mixing the test–retest stability of the SES with the
changes in the self-esteem itself. Conﬁdence intervals of
95% for the correlation coefﬁcients were computed based
on Fisher’s z-transformation.
The correlation with other ADHD scales was evaluated
using Pearson’s correlation coefﬁcients (with 95% CI)—
for weeks 0 and 8 as well as for changes from week 0 to
8—between the total score and the two subscales of the
SES on the one hand and (1) ADHD-RS total score and
subscores, (2) CGI-Severity of ADHD, (3) CGI-Improve-
ment of ADHD (only for changes), and (4) GIPD total
score for each perspective on the other hand.
The inﬂuence of baseline covariates on the development
of self-esteem was assessed by providing mixed models for
repeated measurements for the total and the subscales of
the SES. The models included terms for week, baseline
value, gender, ADHD subtype, age at diagnosis, age at ﬁrst
occurrence of ADHD symptoms, comorbid oppositional
deﬁant disorder (ODD)/conduct disorder (CD), affective
disorders, age, family setting, previous methylphenidate
medication, alcohol/tobacco use, and the respective inter-
actions with week.
Results
Patient population and disposition
A total of 159 patients were enrolled in the study and
started treatment with atomoxetine. 137 (86.2%) patients
completed the 8-week treatment period and continued
into the extension period. The extension period was
completed at week 24 by 111 (69.8%) patients. The
reasons for discontinuation were lack of efﬁcacy (6.3%),
protocol violation (5.7%), adverse event (4.4%), patient
decision (5.0%), parent/caregiver decision (3.8%), patient
lost to follow-up (1.3%) physician decision (1.3%), pre-
existing condition (0.6%), and entry criteria exclusion
(0.6%).
Baseline patient and disease characteristics
Table 2 shows demographics and background data with a
potential impact on self-esteem. The majority of ADHD
patients were boys (78.6%). The combined subtype of
ADHD was diagnosed in 68 (54.4%) boys and 13 (38.2%)
girls [total: 81 patients (50.9%)], and the predominantly
inattentive subtype in 53 (42.4%) boys and 20 (58.8%)
girls [total: 73 patients (45.9%)]. Consisting of only ﬁve
subjects, the subgroup of patients with ADHD, not other-
wise speciﬁed (NOS) was too small for further detailed
subgroup analyses. There were no patients meeting the
DSM-IV-TR criteria for the predominantly hyperactive–
impulsive subtype. For the entire patient sample, the mean
time span between ﬁrst occurrence of symptoms (patient
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123report) and ﬁrst professional diagnosis amounted to
approximately 5.5 years.
According to the age group enrolled (12–17 years),
almost all patients were in secondary education at baseline
(for details see Table 2). The majority of patients (104,
65.4%) were living in a nuclear family, 21 (13.2%) with
their single mother, and 18 (11.3%) with a step parent. The
remaining 16 (10.1%) patients were living with their single
father, foster parents, extended family, independently, in
supervised accommodation, or with adoptive parents
(summarized as ‘Other’ in Table 2).
Of the 159 patients, 137 (86.2%) had previously been
treated with medication for ADHD. Compounds most fre-
quently used had been short-acting methylphenidate
(N = 119, 74.8%) and/or long-acting methylphenidate
(N = 92, 57.9%). Most frequent psychiatric comorbidities
were conduct disorder (N = 29, 18.2%) and oppositional
deﬁant disorder (N = 21, 13.2%) as evaluated by the
investigator.
The mean atomoxetine dose given during the ﬁrst week
of treatment was 0.51 mg/kg per day (SD 0.06, minimum
0.40 mg/kg per day, maximum 0.60 mg/kg per day).
Thereafter, the mean doses ranged between 1.17 and
1.19 mg/kg per day (minimum 0.40, maximum 1.40 mg/kg
per day).
Table 3 shows patients’ baseline data for the scales
used. Self-esteem, as assessed by the mean (±SD) SES
total score (all patients 20.4 ± 5.1), was lower [not sig-
niﬁcant (n.s.)] in female patients (18.8 ± 5.8) compared to
male patients (20.8 ± 4.9), and in those patients with
combined ADHD subtype (19.5 ± 5.2) compared to those
with predominantly inattentive ADHD (21.6 ± 5.0). This
pattern was also observed for the SES subscores.
Psychometric validation of the Rosenberg SES scale
Principal component analysis and factor analysis
Figure 1a and b show the correlations resulting from the
principal component analyses at baseline and week 8,
respectively. The items 2, 5, 6, 8, and 9 are marked with an
‘‘a’’ as they were reversed as stated earlier. All items cor-
related positively with the ﬁrst component (C1). The second
component (C2) distinguished between the items related to
the two subscales, i.e., items 2, 5, 6, 8, and 9 were positively
correlated with C2, whereas the others were negatively
correlated. This structure was already observed at baseline,
but it became very clear at week 8. The factor analyses at
baseline and at week 8 conﬁrmed that the scale consists of
two subscales. The ﬁrst two eigenvalues were larger than 1
and also most of the variance could be explained by these
ﬁrst two factors. The loadings onto the factors resembled
the correlations with the principal components showing the
same structure of the items.
Missing values
The percentage of missing values was 2.47% (31 missing,
1,222 non-missing) for the SES total score, indicating a
tolerable lack of information. For the subscores, the per-
centages of missing values were even lower, with 2.15%
(27 missing, 1,226 non-missing) for the ‘self-conﬁdence’
and 1.04% (13 missing, 1,240 non-missing) for the ‘self-
liking’ subscore.
Table 2 Patient characteristics (all patients, N = 159)
Patient characteristics
Boys/girls, N (%) 125/34 (78.6/21.4)
Age, mean ± SD (years) 14.1 ± 1.5
Age at diagnosis 9.8 ± 2.8
Age at ﬁrst occurrence of symptoms 4.3 ± 2.2
Educational status, N (%)
a
Secondary school: ‘Hauptschule’
b 56 (35.2)
Secondary school: ‘Realschule’
b 54 (34.0)
Secondary school: ‘Gymnasium’
b 32 (20.1)
Vocational school 4 (2.5)
Special needs school 7 (4.4)
Elementary school 3 (1.9)
Family setting, N (%)
Nuclear family 104 (65.4)
Single mother 21 (13.2)
Step parents 18 (11.3)
Other 16 (10.1)
Never consumed alcohol, N (%) 119 (74.8)
Never smoked, N (%) 131 (82.4)
ADHD subtype, N (%)
c
Combined 81 (50.9)
Predominantly inattentive 73 (45.9)
ADHD, not otherwise speciﬁed 5 (3.1)
Previous medication, N (%) 137 (86.2)
Long-acting methylphenidate 92 (57.9)
Short-acting methylphenidate 119 (74.8)
Most frequent psychiatric comorbidities, N (%)
d
Conduct disorder 29 (18.2)
Oppositional deﬁant disorder 21 (13.2)
Emotional disorder 4 (2.5)
Depressed mood 2 (1.3)
ADHD attention-deﬁcit/hyperactivity disorder; SD standard deviation
a Educational status was missing for three patients
b In Germany, there are three different types of secondary schools,
‘Hauptschule’ (lowest qualiﬁcation), ‘Realschule’ (intermediate
qualiﬁcation), and ‘Gymnasium’ (highest qualiﬁcation)
c According to diagnostic and statistical manual of mental disorders,
fourth edition
TM
d Based on investigator’s clinical assessment (y/n)
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123Floor and ceiling effects
At baseline, ﬂoor effects (SES total score = 0) were 0%
for the total score, 0.63% for the subscore ‘self-conﬁ-
dence’, and 0% for the subscore ‘self-liking’. The ceiling
effects (SES total score = 30, subscores = 15) were
0.63% for the total score, 1.27% for the subscore ‘self-
conﬁdence’, and 12.03% for the subscore ‘self-liking’. At
week 8, ﬂoor effects remained at 0% for the total score,
increased to 0.76% for the self-conﬁdence subscore, and
remained at 0% for the self-liking subscore. The ceiling
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123effects increased to 21.97% for the total score, 24.24% for
the ‘self-conﬁdence’ subscore, and 43.18% for the ‘self-
liking’ subscore.
Test–retest reliability
Pearson’s correlation between ratings at weeks 6 and 8 was
0.87 [CI 0.82–0.91] for the SES total score, 0.81 [CI 0.74–
0.86] for the ‘self-conﬁdence’ subscore, and 0.84 [CI 0.77–
0.88] for the ‘self-liking’ subscore. The respective Cohen’s
Kappas were 0.71 [CI 0.65–0.78] for the total score, 0.65
[CI 0.57–0.73] for the ‘self-conﬁdence’ subscore, and 0.72
[CI 0.64–0.80] for the ‘self-liking’ subscore. These results
indicate a moderate to good test–retest reliability within a
period of 2 weeks.
Internal consistency
Cronbach’s alpha indices representing internal consistency
of the SES total score, the ‘self-conﬁdence’ subscore, and
the ‘self-liking’ subscore were 0.823 [CI 0.778; 0.862],
0.787 [CI 0.729; 0.836], and 0.794 [CI 0.739; 0.841] at
baseline, respectively. At week 8, the Cronbach’s alpha for
the scores were 0.906 [CI 0.880; 0.928], 0.904 [CI 0.876;
0.928], and 0.891 [CI 0.858; 0.917], respectively. Except
for the baseline rating of the subscores, all Cronbach’s
alpha values were above 0.80, indicating a good to excel-
lent internal consistency of the scale.
Correlation with other scales
As shown in Table 4, the Pearson’s correlations between
the SES total score and the two subscale scores with the
other scale scores were relatively weak at baseline, ranging
from -0.05 to -0.39.
At baseline, for the SES total score, the correlation was
strongest with the GIPD score representing the patient
perspective (-0.39; CI -0.51 to -0.24), followed by the
physician-rated GIPD score (-0.21; CI -0.35 to -0.05),
while it showed a weak correlation with the parents’ GIPD
score (-0.09; CI -0.25 to 0.07). The correlations between
the two subscales and the other scores were generally
weak. Over time, the correlations increased in the total
score and the self-liking subscore (n.s.). The correlation
was strongest between the SES total score and the GIPD
score (patient perspective: -0.49; CI -0.61 to -0.34), and
Table 4 Correlations between the Rosenberg Self-Esteem total score
and the two subscores with the ADHD-RS total score, ADHD-RS
hyperactivity/impulsivity subscale score, ADHD-RS inattention
subscale, GIPD score (patient, parent, physician perspectives), and
the CGI-Severity score at weeks 0, 8, and changes from baseline
(Pearson correlation coefﬁcients with 95% CIs)
Week With SES total score With SES self-conﬁdence With SES self-liking
ADHD-RS total score 0 -0.14 [-0.29; 0.02] -0.09 [-0.24; 0.07] -0.15 [-0.3; 0.01]
8 -0.15 [-0.31; 0.02] -0.05 [-0.22; 0.12] -0.22 [-0.38; -0.05]
Changes -0.17 [-0.33; 0] -0.07 [-0.24; 0.1] -0.19 [-0.35; -0.02]
ADHD-RS hyp./impuls.subscore 0 -0.09 [-0.24; 0.07] -0.05 [-0.21; 0.11] -0.1 [-0.25; 0.06]
8 -0.1 [-0.27; 0.07] -0.03 [-0.2; 0.15] -0.16 [-0.32; 0.01]
Changes -0.12 [-0.29; 0.05] -0.05 [-0.22; 0.13] -0.14 [-0.3; -0.03]
ADHD-RS inattentive subscore 0 -0.16 [-0.31; 0] -0.11 [-0.26; 0.05] -0.16 [-0.31; -0.01]
8 -0.17 [-0.33; 0] -0.06 [-0.23; 0.11] -0.24 [-0.4; -0.07]
Changes -0.18 [-0.34; -0.01] -0.08 [-0.25; 0.09] -0.21 [-0.37; -0.04]
GIPD score (patient perspective) 0 -0.39 [-0.51; -0.24] -0.31 [-0.44; -0.16] -0.34 [-0.48; -0.2]
8 -0.49 [-0.61; -0.34] -0.35 [-0.49; -0.18] -0.51 [-0.63; -0.37]
Changes -0.06 [-0.23; 0.12] -0.07 [-0.25; 0.11] -0.04 [-0.21; 0.14]
GIPD score (parent perspective) 0 -0.09 [-0.25; 0.07] -0.06 [-0.22; 0.1] -0.1 [-0.25; 0.06]
8 -0.31 [-0.46; -0.14] -0.21 [-0.37; -0.04] -0.34 [-0.48; -0.17]
Changes -0.1 [-0.28; 0.08] -0.07 [-0.24; 0.11] -0.13 [-0.29; 0.05]
GIPD score (physician perspective) 0 -0.21 [-0.35; -0.05] -0.16 [-0.31; 0] -0.19 [-0.33; -0.03]
8 -0.3 [-0.45; -0.13] -0.19 [-0.35; -0.01] -0.35 [-0.49; -0.18]
Changes -0.02 [-0.2; 0.16] 0.06 [-0.12; 0.23] -0.1 [-0.27; 0.08]
CGI-severity 0 -0.17 [-0.32; -0.01] -0.11 [-0.26; 0.05] -0.17 [-0.32; -0.01]
8 -0.23 [-0.38; -0.06] -0.16 [-0.32; 0.01] -0.24 [-0.4; -0.08]
CGI-improvement Changes -0.17 [-0.34; 0] -0.14 [-0.3; 0.04] -0.15 [-0.31; 0.03]
ADHD attention-deﬁcit/hyperactivity disorder; ADHD-RS ADHD-rating scale (parent-rated, investigator-administered and scored); CGI-S/I
clinical global impression-severity/improvement scale; GIPD global impression of perceived difﬁculties; SES Rosenberg Self-Esteem Scale
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123the self-liking subscore and the GIPD score (patient per-
spective: -0.51; CI -0.63 to -0.37).
Courses of the SES scores over time (unifactorial)
The mean SES total score statistically signiﬁcantly
increased in the ﬁrst 2 weeks of treatment with atomoxe-
tine, from 20.4 [95% CI 19.6; 21.2] points at baseline to
22.6 [CI 21.8; 23.4] points at week 2 (Fig. 2a). By week 8,
it was reported at 23.4 [CI 22.5; 24.4] points and by the end
of week 24, it was reported at 23.9 [CI 22.9; 24.9] points.
Both the courses of the mean ‘self-conﬁdence’ subscore
and of the mean ‘self-liking’ subscore followed the general
pattern of the mean SES total score (Fig. 2b). From week 1
onwards, the scores on the ‘self-liking’ subscale were
signiﬁcantly higher than the scores on the ‘self-conﬁdence’
subscale throughout the study.
At baseline, the mean SES total score of female patients
was lower (n.s.) than the mean score of male patients (18.8
[CI 16.8; 20.9] vs. 20.8 [CI 19.9; 21.7). Over time, the
difference between the gender groups decreased (Fig. 3a).
At weeks 8 and 12, female patients even had slightly higher
mean scores (n.s.) than male patients (female patients,
week 8: 23.7 [CI 21.5; 25.9], week 24: 23.7 [CI 21.6; 25.7],
male patients, week 8: 23.4 [CI 22.3; 24.5], week 24: 24.0
[CI 22.8; 25.1]).
The course of the mean SES total score was observed as
largely parallel for both ADHD subtypes (Fig. 3b). Over
the entire time period, patients of the combined subtype
had slightly lower scores (n.s.) than patients of the
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123predominantly inattentive subtype. This difference did not
reach statistical signiﬁcance at any time.
With regard to the subscales, the female patients
reported lower (n.s.) ‘self-conﬁdence’ values compared to
the male patients at baseline (Fig. 4a). After treatment
start, this numerical proportion reversed, with higher self-
conﬁdence values for female than for male patients
throughout the study. However, these differences did not
reach statistical signiﬁcance at any time. With regard to
‘self-liking’, females had slightly lower mean scores (n.s.)
compared to the male patients during the study (Fig. 4b).
The patient group with the combined subtype was again
associated with slightly lower mean ‘self-conﬁdence’
scores than the predominantly inattentive subtype. For the
self-liking subscore, there were no relevant differences
between the two subtypes (data not shown).
Inﬂuencing covariates (multifactorial)
The inﬂuence of baseline covariates on the course of self-
esteem over time was analyzed by taking all covariates into
one model, i.e., the inﬂuence of each of the different factors
was controlled for all other factors. None of the covariates,
as listed in Table 2, had a statistically signiﬁcant inﬂuence
on the SES total score or the self-liking subscale score.
Only for two covariates, a signiﬁcant inﬂuence could be
found for the self-conﬁdence subscale score (family set-
ting; educational status): patients living in a nuclear family
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123started with baseline scores similar to patients living in
other family settings, but the increase in scores over time
was higher (P = 0.0057). Although the overall test for
‘educational status of the patient’ was signiﬁcant (interac-
tion with time; P = 0.0242), no clear pattern emerged
looking at speciﬁc types of schools.
Course over time for other scales
The mean ADHD-RS-IV-Parent:Inv total score (OC) sig-
niﬁcantly decreased in the ﬁrst 2 weeks of treatment with
atomoxetine, from 28.4 [95% CI 26.8–29.9] points at base-
lineto16.7[CI15.0–18.4]pointsatweek2.Thisdecreasein
the mean score continued during further treatment (to 11.0
[CI 9.3–12.7] points at week 24). The course of the mean
ADHD-RS total scores was observed as largely parallel for
both ADHD subtypes (cf. Dittmann et al. 2006; Dittmann
et al. 2009). Over the entire time period, patients of the
combined subtype had signiﬁcantly higher scores than
patients of the predominantly inattentive subtype.
With regard to the GIPD score, parents rated the ADHD-
related difﬁculties less severe (n.s.) than physicians at
baseline, but the parent and physician mean total scores
converged as early as week 2 and overlapped for the
remainder of the study. Compared to the parent and phy-
sician ratings, the adolescents perceived their difﬁculties as
signiﬁcantly less severe at most time points throughout the
study. The mean CGI-S-ADHD score for the overall
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123sample signiﬁcantly decreased from 4.8 [95%CI 4.7–5.0] at
baseline to 3.4 [3.2–3.6] at week 8 and stayed stable,
thereafter, until week 24 (3.3 [3.1 to 3.5]).
Tolerability
Investigators reported treatment-emergent adverse events
in 124 (78.0%) patients over the entire study period. In 82
(51.6%) patients, the investigators considered the adverse
event as possibly related to atomoxetine. Adverse events
reported in more than 5% of the patients and rated as
possibly related to atomoxetine were fatigue (N = 42,
26.2%), nausea (N = 22, 13.8%), headache (N = 15,
9.4%), upper abdominal pain (N = 11, 6.9%), decreased
appetite (N = 11, 6.9%), dizziness 9 (5.7%), and vomiting
9 (5.7%). There were eight patients with serious adverse
events, which were considered related to atomoxetine in
two patients (1 patient with severe vomiting; 1 patient with
abdominal pain, dissociation, disturbance in attention,
dizziness, fatigue, and vasoconstriction). Treatment-emer-
gent adverse events led to discontinuation in 7 (4.4%)
patients: alopecia, decreased appetite, drug abuse, fatigue,
vasoconstriction, vertigo, and vomiting in 1 (0.6%) patient
each; except for fatigue and drug abuse, all these adverse
events were rated as possibly related to treatment by the
investigator. Mean laboratory parameters, including liver
function tests, were found within normal ranges with only
minor ﬂuctuations over the course of the study. In vital
signs, slight increases in blood pressure and heart rate were
observed.
Discussion
To our knowledge, this is one of the very few studies
investigating self-esteem in adolescents with ADHD. Fur-
thermore, it is the largest single study focusing on ado-
lescent ADHD patients treated with atomoxetine (Wilens
et al. 2006a, b) for which preliminary results on efﬁcacy
and tolerability have been published elsewhere (Dittmann
et al. 2006; Dittmann et al. 2009; Wehmeier et al. 2008).
Atomoxetine is a non-stimulant treatment option for
ADHD (Banaschewski et al. 2004; Becker et al. 2006) for
which efﬁcacy and tolerability in children and adolescents
have also been demonstrated in a number of placebo-con-
trolled randomized clinical trials (Kelsey et al. 2004;
Michelson et al. 2001, 2002; Spencer et al. 2002).
The ﬁrst objective of this secondary analysis was to
validate the Rosenberg SES in adolescents with ADHD.
We used the German language version of the Rosenberg
Self-Esteem Scale (SES) to assess self-esteem (Ferring and
Filipp 1996; von Collani and Herzberg 2003). Originally, it
was developed as a one-dimensional scale, but some factor
analytic studies have found that self-esteem, as measured
by the SES, can be decomposed into the subcomponents of
‘self-competence’ (i.e., feeling of having skills, abilities,
and talents) and ‘self-liking’ (which relates to moral
character, attractiveness, and other aspects of social worth;
Tafarodi and Swann 2001; Schmitt and Allik 2005). This
concept of dichotomy could also be supported by the
results of the factor analysis in our sample of adolescent
ADHD patients. Further, the scale has shown good test–
retest reliability over a period of 2 weeks, and it was shown
to be internally consistent (all Cronbach’s alpha values
were above 0.80).
Our second objective was to evaluate correlations of the
SES with ADHD scale scores. The correlations between
the patient-rated SES and the other scales were rather weak
for each point in time as well as for change over time
(Table 4). At baseline, we found weak negative correla-
tions between the SES total and the two subscale scores
with the other scale scores, with slight increases in most of
them over time. The strongest correlations were found
between the SES total and the patient-rated GIPD scores,
both representing the patient perspective. The other scales
assess different constructs of the underlying disorder
(ADHD), mostly rated by another person (physician or
parent), showing smaller negative correlations with SES
scores.
In general, correlations with parameters such as ADHD
core symptoms or related perceived difﬁculties were weak
to modest, and thus suggest that the SES assesses an
additional dimension beyond ADHD core symptoms or
ADHD-related difﬁculties. According to our ﬁndings, self-
esteem may be an important individual patient outcome in
patients with ADHD.
The third objective was to investigate self-esteem in
adolescent patients with ADHD during atomoxetine treat-
ment. The relationship between self-esteem and ADHD
treatment, mostly stimulant treatment, has been investi-
gated in several studies, so far with conﬂicting results
(Alston and Romney 1992; Bussing et al. 2000; Frankel
et al. 1999; Treuting and Hinshaw 2001; Hechtman et al.
2004). In their review, Hechtman and Greenﬁeld (2003)
stated that stimulant treatment in childhood had slight
beneﬁts regarding self-esteem compared to untreated
patients with ADHD in the long term. Several studies with
non-stimulant treatment (atomoxetine) also reported that
treatment seemed to improve self-esteem (Perwien et al.
2004, 2006; Prasad et al. 2007) but provided insufﬁcient
data to determine whether medication was responsible for
the observed changes and differences in self-esteem.
In our study, mean self-esteem scores increased within
the ﬁrst 2 weeks of treatment with atomoxetine by week 2.
The achieved level of improvement was kept, thereafter,
until week 24. This increase was accompanied by the
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123improvement of ADHD symptoms (rated by ADHD-RS
and CGI), and ADHD-related difﬁculties (rated by GIPD).
Since there was no placebo control in this study and a
cutoff value (‘‘normal vs. ‘‘abnormal’’) cannot be found in
the literature, the absolute mean scores and observed
changes over time cannot easily be interpreted with respect
to their clinical relevance. However, von Collani and
Herzberg (2003), who used the same revised SES instru-
ment as in our study, reported a mean score value of 22.7
attained in two healthy study groups (N = 285, 58%
female, mean age 33.7 years; N = 117, 58% female, mean
age 30.8 years). Our patients reached mean scores similar
to those published for healthy subjects. Furthermore, the
mean score values of the ‘self-liking’ subscale were
reported as signiﬁcantly higher than the values of the ‘self-
conﬁdence’ subscale throughout the study. But, the dif-
ferent courses of the two subscales only indicate changes
over time and do not allow for a direct comparison refer-
ring to a clinical meaning (e.g., higher/better self-liking
than self-conﬁdence).
Our ﬁndings are in accordance with other atomoxetine
studies: based on a combined analysis from three placebo-
controlled trials of atomoxetine in children and adolescents
with ADHD (mean age 10.4 years) and using the parent-
rated Child Health Questionnaire (CHQ), Perwien et al.
(2004) reported statistically signiﬁcantly lower baseline
ratings on the ‘self-esteem’ section for the ADHD sample
compared to the normative sample (t-score 63.5 vs. 79.8,
respectively). After 7–8 weeks of treatment with ato-
moxetine, this t-score increased to 70.3. From another
open-label long-term atomoxetine trial (mean age
11.1 years) applying the same instrument, a baseline mean
t-score of 39.6 was observed (Perwien et al. 2006). This
t-score increased by 7.9 points after 10 weeks of treatment,
which was maintained during the long-term follow-up
(24 months). The short-term placebo-controlled improve-
ments were statistically signiﬁcant with a small to medium
effect size of 0.32 (Perwien et al. 2004) and long-term
improvements of parent-reported CHQ self-esteem in
young ADHD patients in the open-label study (Perwien
et al. 2006).
In children and adolescents with ADHD (mean age
10.9 years) treated with either atomoxetine or standard
current therapy over 10 weeks, Prasad et al. (2007) found
statistically non-signiﬁcant increases on the self-reported
‘global self-worth’ domain of the Harter instrument
(HSPP) in both groups, with no statistically signiﬁcant
difference between the two treatment groups.
Interestingly, the female patients in our study showed
lower (n.s.) mean total SES scores compared to male
patients at baseline. Over time, the difference between the
gender groups decreased (Fig. 3a). At weeks 8 and 12,
female patients even had higher score values (n.s.) than
male patients. With regard to the subscales (‘self-conﬁ-
dence’, ‘self-liking’), our ﬁndings also suggested potential
differences between male and female adolescent popula-
tions with ADHD. However, the sample size of partici-
pating female patients was too low to deﬁnitively explain
the implications of the different mean scores in both groups
over time, a topic that may deserve further investigation in
respective controlled studies.
In order to determine possibly inﬂuencing baseline
factors, such as age and gender, we analyzed the inﬂuence
of covariates on the development of self-esteem in our
study. Only for the ‘self-conﬁdence’ subscale score, a
signiﬁcant inﬂuence could be found for two covariates
(family setting; educational status): patients living in a
nuclear family started with baseline scores similar to
patients living in other family settings, but the increase in
mean scores over time was signiﬁcantly higher in this
subgroup. Concerning the educational status of the
patients, the overall test was signiﬁcant (self-conﬁdence
subscale only), but with no clear pattern emerging with
regard to the different speciﬁc types of schools. All other
covariates (gender, age, comorbidities, concomitant medi-
cation, ADHD subtype, etc.) were found not to be the
determinants of the improvement of self-esteem during
atomoxetine treatment. Our results leave underlying factors
of the observed increase in self-esteem in adolescent
ADHD patients largely unexplained.
Limitations
The ﬁndings of this study should be interpreted with cau-
tion due to the open-label design. Most importantly, our
study did not include a placebo control sample or an active
comparator arm, so that the degree to which the results
reﬂect drug-speciﬁc effects or time effects remains uncer-
tain. Further, the proportion of patients with concomitant
emotional or depressive comorbidities was low (2.5 and
1.3% only); this may in part explain why we were unable to
show an impact of patients’ comorbidities on self-esteem.
In this study, exploratory with respect to the self-esteem
outcome parameter, no other instrument assessing self-
esteem or emotional problems as perceived by the patients
was used.
In conclusion, the Rosenberg SES can be considered an
internally consistent and reliable measure to assess changes
of self-esteem experienced by adolescents with ADHD.
The dichotomy of the SES (self-liking, self-conﬁdence)
observed in other psychiatric disorders was replicated in
our study population. No baseline factors inﬂuencing self-
esteem over the course of treatment were found. This study
showed that the scale is sensitive to change as indicated by
a signiﬁcant improvement over time. Changes in self-
esteem over the course of this open-label atomoxetine trial
198 R. W. Dittmann et al.
123were self-reported by adolescent patients with ADHD.
According to these ﬁndings, self-esteem may be an
important individual patient outcome beyond the core
symptoms of ADHD deserving further investigation, also
in controlled studies.
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